Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03472313 · ClinicalTrials.gov registry record · Phase 1
Assessment of the Biodistribution and Safety of [18F]MNI-958 in Healthy Subjects
A Phase 1 study, sponsored by Invicro.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT03472313: Completed Phase 1 study, sponsored by Invicro.
NCT03472313 is a Phase 1 study that has completed, run by Invicro. The registered enrollment target is 2 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03472313, a Phase 1 study, has completed, sponsored by Invicro.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
The overall goal of this protocol is to evaluate the biodistribution of \[18F\]MNI-958 also known as APN-0000455 or PM-PBB3, as a tau targeted radiopharmaceutical.
Primary Outcome
Whole body tomographic PET images will be obtained for 6 healthy volunteers, and reviewed visually for assessment of body organ distribution of radioactivity. Volumes of Interest (VOI) will be placed on the visually identified source organs, and subsequently used for all the study PET frames. Activity within these volumes of interest is expressed in units of total radioactivity (kBq). Radioactivity will be corrected for body attenuation, but not for decay, and time activity data (TAC) generated
Interventions
- DRUG [18F]MNI-958
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2017-11-14 |
| Est. Completion | 2018-04-20 |
| Phase | Phase 1 |
What the finished NCT03472313 record still lists
NCT03472313 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which [18F]MNI-958 is the first listed.
NCT03472313 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03472313 about?
NCT03472313 is a clinical study titled "Assessment of the Biodistribution and Safety of [18F]MNI-958 in Healthy Subjects". The overall goal of this protocol is to evaluate the biodistribution of \[18F\]MNI-958 also known as APN-0000455 or PM-PBB3, as a tau targeted radiopharmaceutical.
What is the current status of trial NCT03472313?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2017-11-14. Estimated completion is 2018-04-20.
What interventions are being tested in trial NCT03472313?
The interventions under investigation include: [18F]MNI-958 (DRUG).
Who is sponsoring clinical trial NCT03472313?
This trial is sponsored by Invicro, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03472313's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI